CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Region: Segment Forecast, 2022 – 2029
The global CAR-T cell therapy market size is expected to reach USD 20,566.5 million by 2029 according to a new study published by Polaris Market Research. The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2022 – 2029” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.
Chimeric antigen receptor CAR T therapy is a type of immunotherapy that modifies the immune system of a cancer patient to make it more effective at detecting and killing cancer cells. A protein is added to the surface of CAR T cells during the manufacturing process to assist them in acquiring this focus. This protein is called a chimeric antigen receptor, or CAR.
Diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, follicular lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukaemia (ALL) in pediatric and young adult patients up to the age of 25 are now treated using CAR T treatment. The US Food and Drug Administration has approved five CAR T medicines as of March 2021. (FDA).
CAR-T treatment is growing rapidly due to rising cancer cases. Additionally, technical advancements of diagnostic techniques in this industry, growing awareness among the people, and the increase in the geriatric population are contributing to and providing significant potential for industry growth.
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. CAR-T Cell Therapy Market Insights
- 4.1. CAR-T Cell Therapy Market – Industry Snapshot
- 4.2. CAR-T Cell Therapy Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.2. Restraints and Challenges
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Value Chain Analysis
- 4.6. CAR-T Cell Therapy Industry trends
- 4.7. COVID-19 Impact Analysis
- 5. Global CAR-T Cell Therapy Market, by Target Antigen
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global CAR-T Cell Therapy, by Target Antigen, 2017 - 2029 (USD Million)
- 5.3. CD19/CD22
- 5.3.1. Global CAR-T Cell Therapy Market, by CD19/CD22, by Region, 2017 - 2029 (USD Million)
- 5.4. BCMA (B-Cell Maturation Antigen)
- 5.4.1. Global CAR-T Cell Therapy Market, by BCMA (B-Cell Maturation Antigen), by Region, 2017 - 2029 (USD Million)
- 5.5. Others
- 5.5.1. Global CAR-T Cell Therapy Market, by Others, by Region, 2017 - 2029 (USD Million)
- 6. Global CAR-T Cell Therapy Market, by Indication
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
- 6.3. Diffuse Large B-Cell Lymphoma (DLBCL)
- 6.3.1. Global CAR-T Cell Therapy Market, by Diffuse Large B-Cell Lymphoma (DLBCL), by Region, 2017 - 2029 (USD Million)
- 6.4. Acute Lymphoblastic Leukemia (ALL)
- 6.4.1. Global CAR-T Cell Therapy Market, by Acute Lymphoblastic Leukemia (ALL), by Region, 2017 - 2029 (USD Million)
- 6.5. Chronic Lymphocytic Leukemia (CLL)
- 6.5.1. Global CAR-T Cell Therapy Market, by Chronic Lymphocytic Leukemia (CLL), by Region, 2017 - 2029 (USD Million)
- 6.6. Multiple Myeloma (MM)
- 6.6.1. Global CAR-T Cell Therapy Market, by Multiple Myeloma (MM), by Region, 2017 - 2029 (USD Million)
- 6.7. Follicular Lymphoma (FL)
- 6.7.1. Global CAR-T Cell Therapy Market, by Follicular Lymphoma (FL), by Region, 2017 - 2029 (USD Million)
- 6.8. Others
- 6.8.1. Global CAR-T Cell Therapy Market, by Others, by Region, 2017 - 2029 (USD Million)
- 7. Global CAR-T Cell Therapy Market, by Geography
- 7.1. Key findings
- 7.2. Introduction
- 7.2.1. CAR-T Cell Therapy Market Assessment, By Geography, 2017 - 2029 (USD Million)
- 7.3. CAR-T Cell Therapy Market – North America
- 7.3.1. North America: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
- 7.3.2. North America: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
- 7.3.3. CAR-T Cell Therapy Market – U.S.
- 7.3.3.1. U.S.: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
- 7.3.3.2. U.S.: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
- 7.3.4. CAR-T Cell Therapy Market – Canada
- 7.3.4.1. Canada: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
- 7.3.4.2. Canada: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
- 7.4. CAR-T Cell Therapy Market – Europe
- 7.4.1. Europe: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
- 7.4.2. Europe: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
- 7.4.3. CAR-T Cell Therapy Market – France
- 7.4.3.1. France: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
- 7.4.3.2. France: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
- 7.4.4. CAR-T Cell Therapy Market – Germany
- 7.4.4.1. Germany: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
- 7.4.4.2. Germany: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
- 7.4.5. CAR-T Cell Therapy Market – Switzerland
- 7.4.5.1. Switzerland: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
- 7.4.5.2. Switzerland: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
- 7.5. CAR-T Cell Therapy Market – Asia Pacific
- 7.5.1. Asia Pacific: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
- 7.5.2. Asia Pacific: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
- 7.5.3. CAR-T Cell Therapy Market – China
- 7.5.3.1. China: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
- 7.5.3.2. China: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
- 7.5.4. CAR-T Cell Therapy Market – Japan
- 7.5.4.1. Japan: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
- 7.5.4.2. Japan: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
- 7.6. CAR-T Cell Therapy Market – Rest of World
- 7.6.1. Rest of World: CAR-T Cell Therapy Market, by Indication, 2017 - 2029 (USD Million)
- 7.6.2. Rest of World: CAR-T Cell Therapy Market, by Target Antigen, 2017 - 2029 (USD Million)
- 8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
- 9. Company Profiles
- 9.1. Amgen Inc. (US)
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Bellicum Pharmaceuticals Inc. (US)
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Bluebird Bio (US)
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Caribou Biosciences, Inc. (US)
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Celgene Corporation
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Cellectis
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Celyad
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Gilead Sciences, Inc.
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Intellia Therapeutics
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. Johnson & Johnson
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
- 9.11. Merck KGaA
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
- 9.12. Nanjing Legend Biotechnology Co., Ltd
- 9.12.1. Company Overview
- 9.12.2. Financial Performance
- 9.12.3. Product Benchmarking
- 9.12.4. Recent Development
- 9.13. Noile-Immune Biotech
- 9.13.1. Company Overview
- 9.13.2. Financial Performance
- 9.13.3. Product Benchmarking
- 9.13.4. Recent Development
- 9.14. Novartis International AG
- 9.14.1. Company Overview
- 9.14.2. Financial Performance
- 9.14.3. Product Benchmarking
- 9.14.4. Recent Development
- 9.15. Pfizer Inc.
- 9.15.1. Company Overview
- 9.15.2. Financial Performance
- 9.15.3. Product Benchmarking
- 9.15.4. Recent Development
- 9.16. Sangamo Therapeutics, Inc.
- 9.16.1. Company Overview
- 9.16.2. Financial Performance
- 9.16.3. Product Benchmarking
- 9.16.4. Recent Development
- 9.17. Servier Laboratories
- 9.17.1. Company Overview
- 9.17.2. Financial Performance
- 9.17.3. Product Benchmarking
- 9.17.4. Recent Development
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook